Nitrosonifedipine, a Photodegradation Product of Nifedipine, Suppresses Pharmacologically Induced Aortic Aneurysm Formation

Pharmacology. 2018;102(5-6):287-299. doi: 10.1159/000492577. Epub 2018 Sep 25.

Abstract

Background/aims: We have reported that nitrosonifedipine (NO-NIF), a photodegradation product of nifedipine, has strong antioxidant and endothelial protective effects, and can suppress several cardiovascular diseases in animal models. The objective of the present study was to investigate the effects of NO-NIF on aortic aneurysm formation.

Methods: The mice were infused with β-aminopropionitrile for 2 weeks and angiotensin II for 6 weeks to induce aortic aneurysm formation. The oxidative stress was measured by dihydroethidium staining and nitrotyrosine staining. The expressions of inflammation-related genes were assessed by quantitative real-time PCR and immunohistochemical staining. To clarify the mechanisms of how NO-NIF suppresses vascular cell adhesion molecule (VCAM)-1, endothelial cells were used in in vitro system.

Results: NO-NIF suppressed pharmacologically induced the aortic aneurysm formation and aortic expansion without blood pressure changes. NO-NIF suppressed elastin degradation and matrix metalloproteinase-2 mRNA expression. NO-NIF suppressed the reactive oxygen species-cyclophilin A positive feedback loop. Upregulated mRNA expressions of inflammation-related genes and endothelial VCAM-1 were suppressed by NO-NIF co-treatment in aortae.

Conclusion: NO-NIF has the potential to be a new, nifedipine-derived therapeutic drug for suppressing aortic aneurysm formation by directly improving aortic structure with its strong ability to reduce oxidative stress and inflammation.

Keywords: Aorta; Aortic aneurysm; Nitrosonifedipine; Oxidative stress.

MeSH terms

  • Aminopropionitrile / administration & dosage
  • Angiotensin II / administration & dosage
  • Animals
  • Antigens, Differentiation / metabolism
  • Antioxidants / pharmacology
  • Aortic Aneurysm / chemically induced
  • Aortic Aneurysm / drug therapy*
  • Aortic Aneurysm / metabolism
  • Chemokine CCL2 / metabolism
  • Cyclophilins / metabolism
  • Disease Models, Animal
  • Elastin / metabolism
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Male
  • Matrix Metalloproteinase 2 / metabolism
  • Mice
  • Nifedipine / analogs & derivatives*
  • Nifedipine / pharmacology
  • Nitroso Compounds / pharmacology*
  • Oxidative Stress / drug effects
  • Photolysis
  • Reactive Oxygen Species / metabolism
  • Vascular Cell Adhesion Molecule-1 / metabolism

Substances

  • Antigens, Differentiation
  • Antioxidants
  • Chemokine CCL2
  • Nitroso Compounds
  • Reactive Oxygen Species
  • Vascular Cell Adhesion Molecule-1
  • monocyte-macrophage differentiation antigen
  • Angiotensin II
  • Aminopropionitrile
  • nitrosonifedipine
  • Elastin
  • Matrix Metalloproteinase 2
  • Cyclophilins
  • Nifedipine